Soleno Therapeutics Inc. Stock
€35.22
Your prediction
Soleno Therapeutics Inc. Stock
Pros and Cons of Soleno Therapeutics Inc. in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Soleno Therapeutics (SLNO), the initial impression points towards a company with a challenging financial position. A notable observation is the absence of revenues over the trailing twelve months (TTM), indicating that as of the recent periods, the company has not generated sales. This factor alone is a significant indicator that can raise concerns about the company's immediate financial health and its ability to sustain operations without relying on additional financing.
The lack of profitability is further evidenced by an EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of approximately -$30,096,000, which suggests that the company is currently operating at a loss. Coupled with a negative EPS (Earnings Per Share) and a P/E (Price-to-Earnings) ratio that is not applicable due to the absence of earnings, it becomes clear that the company is facing substantial financial challenges.
Pros of Soleno Therapeutics’ Financials:
Comments
